Application of gilitinib in treatment of recurrent or refractory acute myeloid leukemia with FLT3 mutation
[Objective]To observe the efficacy and safety of gilitinib in the treatment of recurrent or refractory FLT3 mutant acute myeloid leukemia(AML).[Methods]This article is a prospective study of 85 patients with FLT3 mutant AML admitted between June 2020 and April 2022.The grouping method was the number table method,and the enrolled patients were divided into the conventional group(42 cases)and the experimental group(43 cases).The conventional group received routine AMI chemotherapy,while the experimental group received adjuvant treatment with gilitinib.All patients underwent a one-year follow-up after treatment to compare the short-term efficacy and long-term prognosis of the two groups of patients.[Results]Under different treatment regimens,after 1 cycle,2 cycles,and 3 cycles of treatment,β2-MG levels in the experimental group were 5.25±1.33 mg/L,3.31±1.27 mg/L,and 2.66±0.41 mg/L,respectively,lower than those in the conventional group(6.31±2.05 mg/L,4.49±1.88 mg/L,and 3.12±0.72 mg/L).The remission rate of the experimental group after treatment was 88.37％(38/43),which was higher than that of the conventional group(69.05％,29/42)(P＜0.05).During the follow-up period,the PFS and OS of the experimental group were 7.72±2.36 months and 10.45±2.28 months,respectively,which were higher than those of the conventional group(6.41±1.25 months and 9.11±2.72 months).The recurrence rate and mortality rate of the experimental group were 23.26％(10/43)and 16.28％(7/43),respectively,which were lower than those of the conventional group[38.10％(16/42)and 30.95％(13/42)](P＜0.05).The incidence of drug-related side effects in the experimental group was 46.15％(20/43),slightly higher than 42.86％(18/42)in the conventional group(P＞0.05).[Conclusion]Gilitinib combined with conventional chemotherapy can improve the short-term efficacy and long-term prognosis of FLT3 mutant AML patients.This combination therapy does not significantly increase the risk of side effects and has certain promotional value.
Fms like tyrosine kinase 3acute myeloid leukemiagilettinibfirst line chemotherapyclinical application
万方数据
维普
